For our second episode of "Gilles is in the air", Christelle Nilles co-hosts the interview with Dr Natalia Szejko, and together they ask important questions on cannabis-based medicines as a treatment strategy for improving tics.
What is the current evidence for the use of CBM for treatment of tics? How about CBM and comorbid psychiatric disorders? Can CBM also be helpful? What are the most common side effects?
When would you consider treatment with CBM in TS? Are there any particular strains that are preferable? Another controversial topic is the use of CBM in children; could this treatment be also considered in children with tics?
Our guest today, is Professor Kirsten Müller-Vahl from the Hannover Medical School, specialised in neurology and adult psychiatry. Over the past 30 years, she has investigated Tourette syndrome in more than 3,000 patients.
She is the President of the International Alliance for Cannabinoid Medicines (IACM), and past Chair of the ESSTS.
References, studies and papers cited:
- CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders – Results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study. Link
- Abi-Jaoude E, Bhikram T, Parveen F, Levenbach J, Lafreniere-Roula M, Sandor P. A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome. Cannabis Cannabinoid Res. 2023 Oct;8(5):835-845. doi: 10.1089/can.2022.0091. Epub 2022 Aug 30. PMID: 36040329.
- Mosley PE, Webb L, Suraev A, Hingston L, Turnbull T, Foster K, Ballard E, Gomes L, Mohan A, Sachdev PS, Kevin R, Gordon R, Benson M, McGregor IS. Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome. NEJM Evid. 2023 Sep;2(9):EVIDoa2300012. doi: 10.1056/EVIDoa2300012. Epub 2023 Jun 7. PMID: 38320199.
- Müller-Vahl KR, Pisarenko A, Ringlstetter R, Cimpianu CL, Fremer C, Weidinger E, Jenz EB, Musil R, Brunnauer A, Großhennig A. The Effect of Nabiximols on Driving Ability in Adults with Chronic Tic Disorders: Results of a Substudy Analysis of the Double-Blind, Randomized, Placebo-Controlled CANNA-TICS Trial. Cannabis Cannabinoid Res. 2024 Jan 23.
- doi: 10.1089/can.2023.0114. Epub ahead of print. PMID: 38265476.
- Anis S, Zalomek C, Korczyn AD, Lassman S, Rosenberg A, Gurevich T. Licensed Medical Cannabis Use in Gilles de la Tourette Syndrome: A Retrospective Long-term Follow-Up. Cannabis Cannabinoid Res. 2023 May 12. doi: 10.1089/can.2022.0281. Epub ahead of print. PMID: 37172308.
The Frontiers editorial office will be able to provide more information/answer any questions.
Discover the spectacular destination where we shall meet again next summer!
Invited speakers
Per Andrén
Kevin Black
James Leckman
Davide Martino
- Le relazioni si terranno in lingua inglese con traduzione simultanea in italiano
- Accreditamento ECM per medici, psicologi, infermieri
"A brilliant and empathetic comedy narrating the daily life of a boy with Tourette."
(See detailed programme below)
- Prof Andreas Hartmann, France
Neurologist, Department of Neurology, Hôpital de la Pitié-Salpêtrière, Paris, FR - Dr Christelle Nilles, France
Neurologist, Department of Neurology, Rothschild Foundation Hospital, Paris, FR
- Michele Dunlap, Germany
President & Acting Treasurer - Marla Shea, UK/USA
Secretary
- Christina Papakaliatis, Founder
-Healthcare professionals: a round table for discussion with the speakers will be held in the afternoon.
Online registration is mandatory to secure your participation.
- This event is strictly available to adults and minors aged 16-17 years old. Underaged attendees will not be permitted access.
- The seminar is offered for educational purposes; clinical consultations with any of the invited healthcare professionals will not be provided onsite.
- Only registered participants may attend the event. We will regrettably not be able to admit other non-registered visitors accompanying you.
- Tourette Greece
- TTAG
- ESSTS
- Assessment (including differential diagnosis)
- Natural course and prognosis
- Epidemiology
- Causes & mechanisms
- Q&A
- ADHD (Attention Deficit Hyperactivity Disorder)
- OCD (Obsessive-Compulsive Disorder)
- ASD (Autism Spectrum Disorder)
- Mood (anxiety & depression)
- Sleep
- Q&A
- Available treatments
- Clinical cases
- Comprehensive Q&A with the audience